When Local CAR-T Options Are Limited, There May Be Other Paths in China
We help you access leading hematology and CAR-T centers in China.
Confidential case review • We do not charge fees to help you apply.
You may be exploring other options because:
I cannot get it locally
I've exhausted standard treatments
My cancer has relapsed
I'm looking for a superior CAR-T option
A COMPARISION
How China Compares on CAR-T
Complete remission rates: ~40–67% reported for relapsed/refractory lymphoma, and 60–80% for relapsed/refractory B-cell leukemia comparable to global benchmarks for US products
Manufacturing speed: China now has one of the largest CAR-T therapy bases of CAR-T manufacturing anywhere, a 9-day manufacturing turnaround is a life-saving metric compared with a 4-week manufacturing turnaround
High patient volume. Leading centers run high case volumes for CAR-T and hematology, supporting experienced clinical teams at a lower cost.
